Celgene invests $15 million for closer collaboration with cancer drug co.
Celgene (NYSE:CELG) has made a $15 million strategic investment in a cancer drug developer, which gives it a seat on the company’s board and opens up collaboration opportunities down the road. Acetylon Pharmaceuticals uses histone deacetylase or HDAC inhibitors to develop small molecule cancer treatmentsĀ as well as treatments for autoimmune and other diseases. TheĀ lead […]